Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
Adil Daud(University of California, San Francisco), Omid Hamid(Cedars-Sinai Medical Center), Roxana Dronca(Dana-Farber Cancer Institute), Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Xiaoyun Li(Nanjing University), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jill A. Lindia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hassane M. Zarour(University of Pittsburgh)
Cited by 89
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k